{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:30:33Z","timestamp":1775169033965,"version":"3.50.1"},"reference-count":17,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the minimal important change (MIC) and meaningful change value (MCV) of the Disease Activity Index for Psoriatic Arthritis (DAPSA) and the effect size (ES) of DAPSA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study, recruiting 106 patients who agreed to participate in the research from the Department of Dermatology, Xiangya Hospital, between November 1, 2019, and April 1, 2023. An anchor-based method using linear regression analyses was used to determine the MICs and MCVs of the DAPSA. The anchor question assessed whether the patient\u2019s well-being had changed since their previous visit, employing a 5-point Likert scale that ranged from \u201cmuch improved\u201d to \u201cmuch deteriorated.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall MIC value was 8.4 (95% CI 0.01-16.75). The MIC improvement was 9.5 (95% CI 0.89-18.14) and MIC deterioration was 1.1 (95% CI \u22129.81 to 12.05). The overall MCV was 10.5 (95% CI 4.34-16.72). MCV improvement was 11.4 (95% CI 5.95-16.95) and MCV deterioration was 1.1 (95% CI \u22129.81 to 12.05). The ES was 0.6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A change in DAPSA of 8.4 is indicative of an MIC, offering physicians an additional means to contextualize the patient\u2019s perception of disease activity during treatment, and a change in DAPSA of 10.5 is likely to be regarded as MCV. These values can enhance the utility of DAPSA in psoriatic arthritis clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1085","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:25:13Z","timestamp":1710505513000},"page":"678-681","source":"Crossref","is-referenced-by-count":2,"title":["Defining the Minimal Important Change and Meaningful Change Value of the Disease Activity Index for Psoriatic Arthritis: A Chinese Longitudinal Study"],"prefix":"10.3899","volume":"51","author":[{"given":"Yijie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sichun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2024070105201315000_51.7.678.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2024070105201315000_51.7.678.2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/1346-8138.15954","article-title":"Psoriatic arthritis","volume":"48","author":"Umezawa","year":"2021","journal-title":"J Dermatol"},{"key":"2024070105201315000_51.7.678.3","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024070105201315000_51.7.678.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0"},{"key":"2024070105201315000_51.7.678.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.148"},{"key":"2024070105201315000_51.7.678.6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.semarthrit.2021.06.008","article-title":"Outcome measures used in psoriatic arthritis registries and cohorts: a systematic literature review of 27 registries or 16,183 patients","volume":"51","author":"Aouad","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024070105201315000_51.7.678.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2024070105201315000_51.7.678.8","unstructured":"Chen AJ , Da-Xing C , Xiang C , Expert consensus on the treat-to-target strategy for psoriasis with biological agents in China. Int J Dermatol Venereol 2023 March 7 (Epub ahead of print)."},{"key":"2024070105201315000_51.7.678.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02925-y"},{"key":"2024070105201315000_51.7.678.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2024070105201315000_51.7.678.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117945"},{"key":"2024070105201315000_51.7.678.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2024070105201315000_51.7.678.13","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1093\/rheumatology\/keac025","article-title":"Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis","volume":"61","author":"Mulder","year":"2022","journal-title":"Rheumatology"},{"key":"2024070105201315000_51.7.678.14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"2024070105201315000_51.7.678.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"2024070105201315000_51.7.678.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-014-3487-0"},{"key":"2024070105201315000_51.7.678.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.011"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T12:21:19Z","timestamp":1719836479000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3899\/jrheum.2023-1085"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1085","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}